Видео ютуба по тегу Claudin18.2

Targeting CLDN18.2 with zolbetuximab in gastric and GEJ cancer
Targeting CLDN18.2 with zolbetuximab in gastric and GEJ cancer
Emerging approaches in targeting CLDN18.2 in gastric cancer
Emerging approaches in targeting CLDN18.2 in gastric cancer
胃癌 Claudin18 2跃升为一级推荐！74%治疗有新选 #胃癌新靶点 #医学科普
胃癌 Claudin18 2跃升为一级推荐！74%治疗有新选 #胃癌新靶点 #医学科普
Claudin 18.2 and FGFR2b as novel targets in gastric cancer
Claudin 18.2 and FGFR2b as novel targets in gastric cancer
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +4
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +4
The future of gastric cancer treatment beyond ESMO 2023
The future of gastric cancer treatment beyond ESMO 2023
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +25
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +25
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +12
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day +12
Research Progress of Claudin 18.2 CAR-T in Patients with Gastric Cancer
Research Progress of Claudin 18.2 CAR-T in Patients with Gastric Cancer
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day 0
CAR T-Cell Therapy for Pancreatic Cancer - CT041 Claudin18.2, Day 0
Oncology 2
Oncology 2
Salvage CT041 CLDN18.2-specific CAR T-cell therapy for patients with advanced GI malignancies
Salvage CT041 CLDN18.2-specific CAR T-cell therapy for patients with advanced GI malignancies
Рак поджелудочной железы. Закончено второе клиническое исследование. Новые перспективы.
Рак поджелудочной железы. Закончено второе клиническое исследование. Новые перспективы.
35 First Line Therapy for HER2-, PDL1-, CLDN18.2- GEA
35 First Line Therapy for HER2-, PDL1-, CLDN18.2- GEA
Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma
Safety and efficacy of a CLDN18.2-specific CAR T-cell therapy in GI adenocarcinoma
Самый безопасный ноотроп
Самый безопасный ноотроп
Phase II ILUSTRO: 1L zolbetuximab + mFOLFOX6 + nivolumab in CLDN18.2+ mG/GEJ cancer
Phase II ILUSTRO: 1L zolbetuximab + mFOLFOX6 + nivolumab in CLDN18.2+ mG/GEJ cancer
Can Stage 4 Pancreatic Cancer be Cured?
Can Stage 4 Pancreatic Cancer be Cured?
FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma
FAST: a Phase III trial of an anti-CLDN18.2 antibody GEJ adenocarcinoma